Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

21 maj 2026 uppdaterad av: Innovent Biologics (Suzhou) Co. Ltd.

A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBI3005 Combination Therapy in Participants With Advanced Solid Tumors

To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

282

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Has signed a written informed consent form (ICF) and is able to comply with the scheduled study visits and related procedures.
  2. Age ≥ 18 years, irrespective of gender.
  3. Confirmed diagnosis of locally advanced unresectable or metastatic solid tumor.
  4. Expected survival ≥ 12 weeks.
  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
  6. Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days prior to the first study drug administration.
  7. Adequate bone marrow and organ function.

Additional Inclusion Criteria for Cohort 1:

  1. Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC.
  2. Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens.
  3. In the safety run-in phase, NSCLC participants who have received prior standard therapy.
  4. In the cohort expansion phase, participants without driver gene mutations who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease.

Additional Inclusion Criteria for Cohort 2:

  1. Histologically or cytologically confirmed unresectable locally advanced or metastatic non-squamous NSCLC.
  2. In the safety run-in phase, participants should have received prior standard therapy.

    In the cohort expansion phase:

  3. Cohort 2A: NSCLC participants without driver gene mutations (including at least EGFR, ALK, and ROS1, with written documentation) who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease. Participants who received neoadjuvant/adjuvant therapy are eligible if disease recurrence or progression occurred >6 months after the last neoadjuvant/adjuvant therapy.
  4. Cohort 2B: NSCLC participants with tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens, who have experienced disease progression after prior EGFR-TKI therapy.

Additional Inclusion Criteria for Cohort 3

  1. Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC.
  2. Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens.
  3. In the safety run-in phase, participants should have experienced disease progression after prior EGFR-TKI therapy.
  4. In the cohort expansion phase, NSCLC participants who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease. Participants who received neoadjuvant/adjuvant therapy are eligible if disease recurrence or progression occurred >6 months after the last neoadjuvant/adjuvant therapy.

Exclusion Criteria:

  1. Participation in any other interventional clinical study, except for observational (non-interventional) studies or the follow-up period after the end of study treatment in an interventional study.
  2. Prior treatment with antibody-drug conjugate (ADC) drugs bearing a camptothecin or its derivative (topoisomerase I inhibitor) small-molecule payload.
  3. Prior to the first dose of study drug: a) Within 4 weeks: Received intravenous chemotherapy, macromolecular targeted therapy, antibody-drug conjugates, immunotherapy, endocrine therapy, cell therapy, intraperitoneal perfusion chemotherapy, tumor embolization, or interventional chemotherapy. b) Within 2 weeks or 5 half-lives (whichever is shorter): Received oral chemotherapy, small-molecule targeted therapy, or traditional Chinese herbal medicines indicated for anti-tumor treatment. c) Within 4 weeks: Received radical radiotherapy; within 2 weeks: Received palliative radiotherapy. d) Within 2 weeks or 5 half-lives (whichever is shorter): Received strong inhibitors or strong inducers of cytochrome P450 3A4 (CYP3A4). e) Within 4 weeks: Underwent major surgery (craniotomy, thoracotomy, laparotomy, or other surgeries deemed ""major"" by the investigator, excluding puncture biopsy), or has severe unhealed wounds, trauma, or ulcers; within 2 weeks: Underwent laparoscopic exploratory surgery. f) Within 4 weeks: Received live vaccine (mRNA and non-replicating adenovirus vaccines are not considered live vaccines).
  4. Presence of adverse events from prior anti-tumor therapy that have not resolved to Grade 0 or 1 per NCI-CTCAE v5.0 [excluding Grade 2 alopecia, fatigue, pigmentation, insomnia, peripheral neuropathy, hypomagnesemia, and toxicities stably controlled by medication (e.g., hypothyroidism stably controlled by replacement therapy, hypertension with blood pressure stably controlled below 160/100 mmHg by antihypertensive medication)].

Additional Exclusion Criteria for Cohort 1:

  1. History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy.
  2. History of significant toxicity associated with immune checkpoint inhibitor administration that required permanent discontinuation of such therapy.

Additional Exclusion Criteria for Cohort 2:

  1. History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy.
  2. History of significant toxicity associated with immune checkpoint inhibitor administration that required permanent discontinuation of such therapy.
  3. History of hemoptysis within 3 months prior to the first dose (blood volume >2.5 mL per cough or cumulative daily hemoptysis >10 mL), or current active bleeding.

Continuous use of aspirin (>325 mg/day) or other non-steroidal anti-inflammatory drugs known to inhibit platelet function within 2 weeks prior to the first dose."

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Cohort 1:IBI3005+Sintilimab+ Carboplatin+IBI305
Bispecifikt monoklonalt antikropp-camptothecinderivatkonjugat för injektion (Fo-kod: IBI3005)
Anti-PD-1 Monoclonal Antibody
Recombinant humanized anti-VEGF monoclonal antibody
Second-generation platinum-based chemotherapy drugs
Experimentell: Cohort 2:IBI3005+Sintilimab+ Carboplatin
Bispecifikt monoklonalt antikropp-camptothecinderivatkonjugat för injektion (Fo-kod: IBI3005)
Anti-PD-1 Monoclonal Antibody
Second-generation platinum-based chemotherapy drugs
Experimentell: Cohort 3:IBI3005+Limertinib/Osimertinib
Bispecifikt monoklonalt antikropp-camptothecinderivatkonjugat för injektion (Fo-kod: IBI3005)
Third-generation EGFR-TKI
Third-generation EGFR-TKI

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
total överlevnad (OS)
Tidsram: Upp till 3 år
Upp till 3 år
Antal försökspersoner med kliniskt signifikanta förändringar i resultat av fysisk undersökning
Tidsram: Upp till 3 år
Kliniskt signifikanta onormala fysiska undersökningsfynd rapporterade av utredaren.
Upp till 3 år
Antal försökspersoner med kliniskt signifikanta förändringar i vitala tecken
Tidsram: Upp till 3 år
Vitala tecken inklusive kroppstemperatur, puls, andningsfrekvens, SpO2 och blodtryck
Upp till 3 år
progressionsfri överlevnad (PFS)
Tidsram: Upp till 3 år
utvärderat enligt RECIST v1.1-kriterierna.
Upp till 3 år
Number of subjects with adverse events
Tidsram: Up to 3 years
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Up to 3 years
Number of subjects with treatment emergent adverse events
Tidsram: Up to 3 weeks
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Up to 3 weeks
Number of subjects with adverse events of special interest
Tidsram: Up to 3 years
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Up to 3 years
Number of subjects with serious adverse events
Tidsram: Up to 3 years
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Up to 3 years
Dose limiting toxicities (DLTs)
Tidsram: Up to 3 weeks
Dose limiting toxicities (DLTs) to establish MTD and/or RP2D.
Up to 3 weeks
Number of subjects with clinically significant changes in laboratory tests results
Tidsram: Up to 3 years
Clinically significant abnormal laboratory tests results reported by the investigator.
Up to 3 years
Objective Response Rate, (ORR)
Tidsram: Up to 3 years
as evaluated per the RECIST v1.1 criteria.
Up to 3 years
duration of response (DCR)
Tidsram: Up to 3 years
as evaluated per the RECIST v1.1 criteria.
Up to 3 years
time to response (TTR)
Tidsram: Up to 3 years
as evaluated per the RECIST v1.1 criteria.
Up to 3 years
duration of response (DoR)
Tidsram: Up to 3 years
as evaluated per the RECIST v1.1 criteria.
Up to 3 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
anti-drog antikropp (ADA)
Tidsram: Upp till 3 år
Förekomst och karakterisering av anti-läkemedelsantikropp (ADA).
Upp till 3 år
area under the curve (AUC)
Tidsram: Up to 3 years
area under the curve (AUC) of single and multiple doses of IBI3005
Up to 3 years
maximum concentration (Cmax)
Tidsram: Up to 3 years
maximum concentration (Cmax) of single and multiple doses of IBI3005
Up to 3 years
time to maximum concentration (Tmax)
Tidsram: Up to 3 years
time to maximum concentration (Tmax) of single and multiple doses of IBI3005
Up to 3 years
clearance (CL)
Tidsram: Up to 3 years
clearance (CL) of single and multiple doses of IBI3005
Up to 3 years
apparent volume of distribution (V)
Tidsram: Up to 3 years
apparent volume of distribution (V) of single and multiple doses of IBI3005
Up to 3 years
half-life (t1/2)
Tidsram: Up to 3 years
half-life (t1/2) of IBI3005 to the last administration of IBI3005
Up to 3 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juni 2026

Primärt slutförande (Beräknad)

30 juni 2027

Avslutad studie (Beräknad)

30 juni 2028

Studieregistreringsdatum

Först inskickad

21 maj 2026

Först inskickad som uppfyllde QC-kriterierna

21 maj 2026

Första postat (Faktisk)

28 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • CIBI3005A102

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera